Advanced, recurrent, and persistent cervical cancer management: in the era of immunotherapy

HIGHLIGHTS

• What: An exploratory subgroup analysis of this study demonstrated, in those patients with CPS ≥1%, a benefit in OS in favor of the pembrolizumab groups across all subgroups.
• Who: . and collaborators from the melweis University, Hungary Peking Union Medical College, China have published the research work: Advanced, recurrent, and persistent cervical cancer management: in the era of immunotherapy, in the Journal: (JOURNAL)

SUMMARY

Despite being a completely preventable disease, in developing countries, cervical cancer (CC) is a major contributor to cancerrelated deaths in women. PD-L1 expression by tumors enables them . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.